Charles Schwab Investment Management Inc. Decreases Stock Holdings in Generation Bio Co. (NASDAQ:GBIO)

Charles Schwab Investment Management Inc. lowered its position in Generation Bio Co. (NASDAQ:GBIO) by 13.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 367,026 shares of the company’s stock after selling 56,273 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Generation Bio were worth $389,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. FMR LLC boosted its stake in Generation Bio by 0.3% in the third quarter. FMR LLC now owns 5,320,266 shares of the company’s stock valued at $13,141,000 after acquiring an additional 15,656 shares in the last quarter. Baker BROS. Advisors LP lifted its holdings in shares of Generation Bio by 61.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company’s stock valued at $4,804,000 after purchasing an additional 737,988 shares during the last quarter. State Street Corp boosted its position in shares of Generation Bio by 1.2% in the 3rd quarter. State Street Corp now owns 992,188 shares of the company’s stock worth $2,451,000 after purchasing an additional 11,669 shares in the last quarter. Finally, Barclays PLC grew its stake in Generation Bio by 165.5% during the 3rd quarter. Barclays PLC now owns 76,430 shares of the company’s stock worth $189,000 after buying an additional 47,639 shares during the last quarter. Institutional investors own 95.22% of the company’s stock.

Insiders Place Their Bets

In related news, Director Anthony G. Quinn purchased 85,000 shares of the business’s stock in a transaction on Monday, January 13th. The shares were bought at an average cost of $0.97 per share, with a total value of $82,450.00. Following the transaction, the director now owns 299,286 shares of the company’s stock, valued at approximately $290,307.42. This trade represents a 39.67 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 21.10% of the stock is currently owned by insiders.

Generation Bio Price Performance

Shares of GBIO stock opened at $0.41 on Tuesday. The business has a fifty day moving average of $0.64 and a 200 day moving average of $1.36. Generation Bio Co. has a 1 year low of $0.40 and a 1 year high of $4.65. The firm has a market capitalization of $27.14 million, a price-to-earnings ratio of -0.18 and a beta of 2.72.

Generation Bio (NASDAQ:GBIO) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.01). The firm had revenue of $4.19 million during the quarter, compared to analysts’ expectations of $2.92 million. Generation Bio had a negative return on equity of 104.85% and a negative net margin of 782.86%. As a group, equities research analysts expect that Generation Bio Co. will post -1.75 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Generation Bio in a research note on Friday, March 14th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Generation Bio in a research report on Monday, March 17th. Finally, Wedbush reissued an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a research report on Friday, March 14th.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.